Advertisement
Home »

Izokibep Therapy Shows Exceptional Clinical Response for HS

Mar 23, 2023

REFERENCES & ADDITIONAL READING

  1. Papp K. Izokibep, a novel IL-17A inhibitor, demonstrates HiSCR100 responses in moderate-to-severe hidradenitis suppurativa: Open-label part A results of a phase 2b/3 study. S025, AAD Annual Meeting 2023, 17-21 March, New Orleans.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement